Company intelligence / Profile preview

Kenta Biotech AG

Bern/Zürich area* (HQ listed as Rehhagstrasse 79 CH–3018), Switzerlandkentabiotech.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Kenta Biotech developed a pipeline of fully human monoclonal antibody therapies targeting severe infectious diseases, especially hospital-acquired bacterial and viral infections. Their lead program reached Phase 3 clinical trials. In May 2013, Aridis Pharmaceuticals acquired their anti-infection product portfolio and discovery technology. The company’s proprietary MabIgX® platform enabled the rapid generation of highly specific therapeutic mAbs.

Therapeutic areas: Infectious Diseases
Modalities: monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

2 assets

KBRV201

Pre-clinical

Indications: Respiratory syncytial virus infection

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Kenta Biotech AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kenta Biotech AG.

Explore the full profile